Hansa Biopharma — Oktober 2021
-
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
-
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
- Selecta obtains from Genovis exclusive worldwide rights to Xork, a differentiated IgG protease - - Selecta combines ImmTOR™ platform with Genovis’ novel IgG protease, Xork, to unlock the full potential of transformative gene therapies and treat certain IgG-mediated autoimmune diseases - - This novel combination has the potential to simultaneously address two of the key hurdles in gene therapy today: pre-existing immunity and the inability to re-dose AAV gene therapies - WATERTOWN, Mass., Oct.
Yahoo Finance (finance.yahoo.com)
-
-
Der foregår for mange skumle ting i den aktie…investorerne bliver skræmt væk af de rutscheture og mærkelige udsving….alt for meget spekulation i Hansa.
-
Må indrømme at min lyst til at smide flere penge efter Hansa forsvinder, med alt det manipulation og mærkelige udsving. Beholder dog dem jeg har p.t
-
Ved ikke af, at der der noget mystisk, eller manipulerende der foregår.. nu har en tidligere partner, Genovis (som Hansa var storejer af), indgået en licensaftale på det samme stof, som Hansa skal til at markedsføre.. det lyder til gengæld mærkeligt, at de kan det (at Hansa ikke har enten patent, eller lavet en aftale med Genovis da de solgte), men det hører vi nok mere om de kommende dage.
-
Sikkert bare en god købsmulighed, men jeg holder mig også væk fra købsknappen til vi hører mere.
-
Så gik den i plus igen….kun Avanza og Nordnet der sælger….Morgan Stanley køber pænt ind….mon ikke det bare var lidt hurtig panik?
-
-
Hansa Biopharma is very confident in the strength of its proprietary IgG cleaving enzyme platform as well as the Company’s patent portfolio for therapeutic use across transplantation, autoimmunity, gene therapy and other therapeutic area to treat and prevent an IgG mediated condition.
The Company has no further comments related to the announcement from Genovis and Selecta Bioscience
Best
KlausKlaus Sindahl
Head of Investor Relations -
Jeg har lige nu svært ved at se, hvordan de skulle sige intet. Det er vel overvejende en kommentar uden indhold.
-
Det er i hvert fald nok ikke den sidste del af historien. Jeg tror ikke at han tør bruge definitive vendinger af samme årsag.
-
Hansa Biopharma: Interview with CEO Søren Tulstrup (video)
(25/10-2021)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind